REFERENCES
- Holden B A, La Hood D, Grant T, et al. Gram-negative bacteria can induce contact lens related acute red eye (CLARE) responses. CLAO J. 1996; 22: 47–52, [PUBMED], [INFOTRIEVE], [CSA]
- Laibson P R, Donnenfeld E D. Corneal ulcers related to contact lens use. Contact Lenses and External Disease, E J Cohen. Little, Brown & Company, Boston 1986; 3–14
- Cheng K, Leung D, Hoekman H, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet 1999; 354: 181–184, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kang P J, Hauser A R, Apodaca G, et al. Identification of Pseudomonas aeruginosa genes required for epithelial cell injury. Mol Microbiol. 1997; 24: 1249–1262, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yahr T L, Mende-Mueller L M, Friese M B, Frank D W. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J. Bacteriol. 1997; 179: 7165–7168, [PUBMED], [INFOTRIEVE], [CSA]
- Frank D W. The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol. 1997; 26: 621–629, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A. Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments. Mol Microbiol. 1997; 25: 1125–1139, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Finck-Barbancon V, Goranson J, Zhu L, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol. 1997; 25: 547–557, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hauser A R, Kang P J, Engel J N. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence. Mol Microbiol. 1998; 27: 807–818, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yahr T L, Vallis A J, Hancock M K, et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Nat Acad Sci USA 1998; 95: 13899–13904, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fleiszig S M, Wiener-Kronish J P, Miyazaki H, et al. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infec Immun. 1997; 65: 579–586, [CSA]
- Coburn J, Frank D W. Macrophages and epithelial cells respond differently to the Pseudomonas aeruginosa type III secretion system. Infec Immun. 1999; 67: 3151–3154, [CSA]
- Hauser A R, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Criti Care Medi. 2002; 30: 521–528, [CROSSREF], [CSA]
- Roy-Burman A, Savel R H, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis. 2001; 183: 1767–1774, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fleiszig S M, Lee E J, Wu C, et al. Cytotoxic strains of Pseudomonas aeruginosa can damage the intact corneal surface in vitro. CLAO J. 1998; 24: 41–47, [PUBMED], [INFOTRIEVE], [CSA]
- Zhu H, Thuruthyil S J, Willcox M DP. Determination of quorum-sensing signal molecules and virulence factors of Pseudomonas aeruginosa strains isolated from contact lens-induced microbial keratitis. J Med Microbiol. 2002; 51: 1063–1070, [PUBMED], [INFOTRIEVE], [CSA]
- Cole N, Willcox M D, Fleiszig S M, et al. Different strains of Pseudomonas aeruginosa isolated from ocular infections or inflammation display distinct corneal pathologies in an animal model. Curr Eye Res. 1998; 17: 730–735, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cowell B A, Willcox M D, Hobden J A, et al. An ocular strain of Pseudomonas aeruginosa is inflammatory but not virulent in the scarified mouse model. Exp Eye Res. 1998; 67: 347–356, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Morihara K, Homma J Y. Pseudomonas Proteases. CRC Press Inc., Boca Raton, FL 1985
- Caballero A, Thibodeaux B, Marquart M, et al. Pseudomonas keratitis: Protease IV gene conservation, distribution, and production relative to virulence and other Pseudomonas proteases. Invest Ophthalmol Visual Sci. 2004; 45: 522–530, [CROSSREF], [CSA]
- Bower K S, Kowalski R P, Gordon Y J. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996; 121: 712–715, [PUBMED], [INFOTRIEVE], [CSA]
- O'Brien T P, Maguire M G, Fink N E, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol. 1995; 113: 1257–1265, [PUBMED], [INFOTRIEVE], [CSA]
- Chaudhry N A, Flynn H W, Murray T G, et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999; 128(4)509–510, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Alexandrakis G, Alfonso E C, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000; 107(8)1497–1502, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Garg P, Sharma S, Rao G N. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999; 106: 1319–1323, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kunimoto D Y, Sharma S, Garg P, Rao G N. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology 1999; 106: 80–85, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tassios P T, Gennimata V, Maniatis A N, et al. Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. J Clin Microbiol. 1998; 36: 897–901, [PUBMED], [INFOTRIEVE], [CSA]
- Bouza E, Garcia-Garrote F, Cercenado E, et al. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain. Antimicrob Agents Chemother. 1999; 43: 981–982, [PUBMED], [INFOTRIEVE], [CSA]
- Thuruthyil S J, Zhu H, Willcox M DP. Serotype and adhesion of Pseudomonas aeruginosa isolated from contact lens wearers. Clin Exp Ophthalmol. 2001; 29: 147–149, [CROSSREF], [CSA]
- Berthelot P, Attree I, Plesiat P, et al. Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates:evidence for a possible association between O serotypes and exo genes. J. Infect Dis. 2003; 188: 512–518, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Faure K, Shimabukuro D, Ajayi T, et al. O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa. J Clin Microbiol. 2003; 41: 2158–2160, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lakkis C, Fleiszig S MJ. Resistance of Pseudomonas aeruginosa isolates to hydrogel contact lens disinfection correlates with cytotoxic activity. J Clin Microbiol. 2001; 39: 1477–1486, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Allewelt M, Coleman F T, Grout M, et al. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infec Immun. 2000; 68: 3998–4004, [CROSSREF], [CSA]
- Lomholt J A, Poulsen K, Kilian M. Epidemic population structure of Pseudomonas aeruginosa:Evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. Infect. Immun. 2001; 69: 6284–6295, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bell S M, Gatus B J, Pham J N. Antibiotic Susceptibility Testing by the CDS Methods: A Concise Laboratory Manual. South Eastern Area Laboratory Services, SydneyAustralia 1999
- Cowell B A, Weissman B A, Yeung K K, et al. Phenotype of Pseudomonas aeruginosa isolates causing corneal infection between 1997 and 2000. Cornea 2003; 22: 131–134, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Winstanley C, Kaye S B, Neal T J, et al. Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis. J Med Microbiol. 2005; 54: 519–526, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fleiszig S M, Zaidi T S, Preston M J, et al. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun. 1996; 64: 2288–2294, [PUBMED], [INFOTRIEVE], [CSA]
- Feltman H, Schulert G, Khan S, et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147: 2659–2669, [PUBMED], [INFOTRIEVE], [CSA]
- Dacheux D, Toussaint B, Richard M, et al. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infec Immun. 2000; 68: 2916–2924, [CROSSREF], [CSA]
- Woods D E, Sokol P A. Role of Pseudomonas aeruginosa extracellular enzymes in lung disease. Clin Investi Medi Medecine Clinique et Experimentale. 1986; 9: 108–112, [CSA]
- Rumbaugh K P, Griswold J A, Hamood A N. Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection:variations in virulence factors and virulence genes. J. Hosp Infect. 1999; 43: 211–218, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schulert G S, Feltman H, Rabin S D, et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital–acquired pneumonia. J Infec Dis. 2003; 188: 1695–1706, [CROSSREF], [CSA]
- Cowell B A, Twining S S, Hobden J A, et al. Mutation of lasA and lasB reduces Pseudomonas aeruginosa invasion of epithelial cells. Microbiology. 2003; 149: 2291–2299, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhu H, Bandara R, Conibear T CR, Kjelleberg S, et al. Pseudomonas aeruginosa with lasI quorum-sensing deficiency during corneal infection. Invest Ophthalmo Vis Sci. 2004; 45: 1897–1903, [CROSSREF], [CSA]
- Zhu H, Thuruthyil S J, Willcox M DP. Contribution of quorum-sensing systems to the virulence of Pseudomonas aeruginosa during corneal infections. Invest Ophthalmol Vis Sci. 2001; 42: S514, [CSA]
- Hummel K M, Penheiter A R, Gathman A C, Lilly W W. Anomalous estimation of protease molecular weights using gelatin-containing SDS-PAGE. Anal Biochem. 1995; 233: 140–142, [CROSSREF], [CSA]
- Raymond C K, Sims E H, Kas A, et al. Genetic variation at the O-antigen biosynthetic locus in Pseudomonas aeruginosa. J Bacteriol. 2002; 184: 3614–3622, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Farmer J Jr, Weinstein R A, Zierdt C H, Brokopp C D. Hospital outbreaks caused by Pseudomonas aeruginosa: Importance of serogroup O11. J Clin Microbiol. 1982; 16: 266–270, [PUBMED], [INFOTRIEVE], [CSA]
- Elder M J, Morlet N. Endophthalmitis. Clin Expe Ophthalmo. 2002; 30: 394–398, [CROSSREF], [CSA]
- Leibovitch I, Lai T F, Senarath L, et al. Infectious keratitis in South Australia:Emerging resistance to cephazolin. Eur J Ophthalmol. 2005; 15: 23–26, [PUBMED], [INFOTRIEVE], [CSA]
- Kucers A, Crowe S M, Grayson M L, Hoy J F. The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs5th ed. Butterworth-Heinemann, Oxford 1997
- Rhee M K, Kowlski R P, Romanowski E G, et al. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Ame J Ophthalmo. 2004; 138: 226–230, [CROSSREF], [CSA]
- Robinson A, Kremer I, Avisar R, et al. The combination of topical ceftazidime and aminoglycosides in the treatment of refractive pseudomonal keratitis. Graefes Arch Clin Expe Ophthalmol. 1999; 237: 177–180, [CROSSREF], [CSA]
- Lee E J, Truong T N, Mendoza M N, Fleiszig S MJ. A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics. Curr Eye Res. 2003; 27: 289–299, [PUBMED], [INFOTRIEVE], [CSA]
- Marquart M E, Caballero A R, Chomnawang M, et al. Identification of a novel secreted protease from Pseudomonas aeruginosa that causes corneal erosions. Inves Ophthalmol Visi Sci. 2005; 46: 3761–3768, [CSA]